Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7186
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pham, J. P. | - |
dc.contributor.author | Joshua, A. M. | - |
dc.contributor.author | da Silva, Ines Pires | - |
dc.contributor.author | Dummer, R. | - |
dc.contributor.author | Goldinger, S. M. | - |
dc.date.accessioned | 2023-06-07T01:57:06Z | - |
dc.date.available | 2023-06-07T01:57:06Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Current Oncology Reports 25(6):609-621, 2023 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7186 | - |
dc.description.abstract | PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. RECENT FINDINGS: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients. | - |
dc.title | Chemotherapy in cutaneous melanoma: Is there still a role? | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1007/s11912-023-01385-6 | - |
dc.subject.keywords | Chemotherapy | - |
dc.subject.keywords | Immune checkpoint inhibitor | - |
dc.subject.keywords | Melanoma | - |
dc.identifier.journaltitle | Current Oncology Reports | - |
dc.identifier.department | Oncology | - |
dc.identifier.pmid | 36988735 | - |
dc.contributor.wslhd | da Silva, Ines Pires | - |
dc.identifier.affiliation | Medical Oncology, The Kinghorn Cancer Centre, St. Vincent�??s Hospital Sydney, Darlinghurst, NSW, Australia | - |
dc.identifier.affiliation | School of Clinical Medicine, UNSW Medicine and Health, St Vincent�??s Hospital, Darlinghurst, NSW, Australia | - |
dc.identifier.affiliation | Melanoma Institute Australia, The University of Sydney, Wollstonecraft, NSW, Australia | - |
dc.identifier.affiliation | Medical Oncology, Blacktown Hospital, Blacktown, NSW, Australia | - |
dc.identifier.affiliation | Department of Dermatology, University Hospital Zurich, R��mistrasse 100, 8091 Zurich, Switzerland | - |
dc.identifier.affiliation | Faculty of Medicine, University of Zurich, Zurich, Switzerland | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Westmead | - |
dc.type.studyortrial | Review | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.